J. Mejia

发表

Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

J. Ross, K. Hess, G. Hortobagyi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

K. Hess, G. Hortobagyi, L. Pusztai, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Isolated TCR αβ Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8+ T Cells To Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

J. Mejia, J. Granados, H. Guio, 2018, The Journal of Immunology.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.

E. Winer, J. Mejia, V. Karantza, 2021, The Lancet. Oncology.

CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer

Jing Wang, G. Hortobagyi, L. Pusztai, 2007, Breast Cancer Research.

Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule

V. Valero, N. Ibrahim, J. Mejia, 2009, Oncology.

Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study.

Lajos Pusztai, Christos Sotiriou, Kenneth R Hess, 2007, The Lancet. Oncology.

Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer

C. Sotiriou, G. Hortobagyi, L. Pusztai, 2007, Clinical Cancer Research.

Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC)

E. Winer, S. Loi, J. Mejia, 2020 .

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

G. Hortobagyi, L. Pusztai, H. Kuerer, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III study of docetaxel weekly (DW) versus every 3 weeks (D) in patients with metastatic breast cancer: Final results.

G. Hortobagyi, V. Valero, J. Mejia, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)

J. Mejia, V. Karantza, F. André, 2019, Annals of Oncology.

Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer

G. Hortobagyi, V. Valero, J. Mejia, 2008, Cancer.

Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival.

G. Hortobagyi, V. Valero, J. Mejia, 2007, Clinical breast cancer.

Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.

J. Lunceford, E. Winer, J. Mejia, 2020, Journal of Clinical Oncology.

A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer

E. B. Butler, J. Mejia, Jenny C. Chang, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).

D. Cescon, J. Mejia, V. Karantza, 2020 .

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

K. Hess, G. Hortobagyi, L. Pusztai, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC

D. Cescon, J. Mejia, V. Karantza, 2020 .

Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule

V. Valero, N. Ibrahim, J. Mejia, 2009, Oncology.

Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer

G. Hortobagyi, V. Valero, J. Mejia, 2008, Cancer.